Therapeutic Kinase Inhibitors

Volume 355 of the series Current Topics in Microbiology and Immunology pp 135-169


Will Kinase Inhibitors Make it as Glioblastoma Drugs?

  • Ingo K. MellinghoffAffiliated withHuman Oncology and Pathogenesis Program, Department and Neurology, Memorial Sloan-Kettering Cancer Center Email author 
  • , Nikolaus SchultzAffiliated withComputational Biology Program, Memorial Sloan-Kettering Cancer Center
  • , Paul S. MischelAffiliated withDepartment of Pathology, University of California Los Angeles
  • , Timothy F. CloughesyAffiliated withDepartment of Neurology, University of California Los Angeles

* Final gross prices may vary according to local VAT.

Get Access


Kinase inhibitors have emerged as effective cancer therapeutics in a variety of human cancers. Glioblastoma (GBM), the most common malignant brain tumor in adults, represents a compelling disease for kinase inhibitor therapy because the majority of these tumors harbor genetic alterations that result in aberrant activation of growth factor signaling pathways. Attempts to target the Ras—Phosphatidylinositol 3-kinase (PI3K)—mammalian Target of Rapamycin (mTOR) axis in GBM with first generation receptor tyrosine kinase (RTK) inhibitors and rapalogs have been disappointing. However, there is reason for renewed optimism given the now very detailed knowledge of the cancer genome in GBM and a wealth of novel compounds entering the clinic, including next generation RTK inhibitors, class I PI3K inhibitors, mTOR kinase inhibitors (TORKinibs), and dual PI3(K)/mTOR inhibitors. This chapter reviews common genetic alterations in growth factor signaling pathways in GBM, their validation as therapeutic targets in this disease, and strategies for future clinical development of kinase inhibitors for high grade glioma.